Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Over half of refractory AML patients responded to combo

Advani A et al. ASH 2017, Abstract 150.

Key clinical point: MEC plus ixazomib is well tolerated and effective in relapsed/refractory AML.

Major finding: The overall response rate was 53%.

Study details: A phase 1 trial involving 30 patients.

Disclosures: Dr. Advani reported receiving research funding from Takeda/Millenium, and serving as a consultant for Pfizer.

Source: Advani A et al. ASH 2017, Abstract 150.

Read the full article.

Citation:

Advani A et al. ASH 2017, Abstract 150.

This Week's Must Reads

Relevance of Health Literacy to CV Health, Circulation; ePub 2018 Jun 4; Magnani, et al

Diabetes & Long-Term Kidney Disease, Diabetes Care; ePub 2018 Jun 1; Warren, et al

Maternal Loss of Control Over Eating, Am J Clin Nutr; ePub 2018 Jun 5; Micali, et al

Efficacy of Brief Behavioral Treatment for Insomnia, Sleep Medicine; ePub 2018 Jun 2; McCrae, et al

Opioid-Related Adverse Events in Surgical Patients, JAMA Surg; ePub 2018 May 23; Shafi, et al

Must Reads in Oncology

ACS Recommends CRC Screening at Age 45, CA Cancer J Clin; ePub 2018 May 30; Wolf, et al

Lung Cancer Incidence in Young Men & Women, N Engl J Med; 2018 May 24; Jemal, et al

Risk Prediction Models for Lung Cancer Screening , Ann Intern Med; ePub 2018 May 15; Katki, et al

USPSTF: Screening for Prostate Cancer, JAMA; 2018 May 8; Grossman, et al

Cancer Incidence Rates in HIV-Infected Adults, Ann Intern Med; ePub 2018 May 8; Shiels, et al